International Journal For Multidisciplinary Research
E-ISSN: 2582-2160
•
Impact Factor: 9.24
A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal
Home
Research Paper
Submit Research Paper
Publication Guidelines
Publication Charges
Upload Documents
Track Status / Pay Fees / Download Publication Certi.
Editors & Reviewers
View All
Join as a Reviewer
Reviewer Referral Program
Get Membership Certificate
Current Issue
Publication Archive
Conference
Publishing Conf. with IJFMR
Upcoming Conference(s) ↓
WSMCDD-2025
GSMCDD-2025
Conferences Published ↓
RBS:RH-COVID-19 (2023)
ICMRS'23
PIPRDA-2023
Contact Us
Plagiarism is checked by the leading plagiarism checker
Call for Paper
Volume 6 Issue 5
September-October 2024
Indexing Partners
A study of determinants of pulmonary fibrosis in COVID-19 survivors.
Author(s) | Raj Kumar, Rajiv Garg, Surya Kant, S.K. Verma, Santosh Kumar, R.A.S. Kushwaha, Ajay Kumar Verma, Anand Srivastava, Darshan Kumar Bajaj, Ankita Mandal |
---|---|
Country | India |
Abstract | The COVID-19 pandemic has mainly affected the lungs, including many other organs. Many of the patients later developed pulmonary fibrosis. This study was planned to determine the pulmonary fibrosis determinants in post-COVID survivors. Hospital-based, cross-sectional study done over one year. A pre-designed proforma was used to collect necessary information, and follow-up HRCT and other investigations were evaluated. Out of 87 patients, 41.3%(n=36) developed pulmonary fibrosis; the majority, i.e.,66.6%(n=24), were males. Most of them, 49.42%(n=43), belonged to the age group of 51-70 years, among which 48.83%(n=21) developed fibrosis. Among the study subjects, 57.47% (n=50) had different comorbidities, of which 52% (n=26) developed pulmonary fibrosis. The proportion of diabetes was 31/50, out of which 67.7% (n=21, p=0.036) developed pulmonary fibrosis, while 80% (n=4, p=0.014) of patients with thyroid disorders developed pulmonary fibrosis. A total of 27 patients were treated in ICU, out of which 66.67% (n=18) developed pulmonary fibrosis. Pulmonary fibrosis developed more when steroids were not used on 9/19, 47% (n=9), compared to those where steroids were used on 27/68, 39.7% (n=27). Most patients, i.e.,>90% fibrotic, had raised inflammatory markers. About half of the survivors had post-COVID-19 pulmonary fibrosis. This study emphasized the relationship between pulmonary fibrosis and many factors, such as age, comorbidities, ICU admission, steroid usage, inflammatory markers, and secondary infections. |
Keywords | post-covid, pulmonary-fibrosis, comorbidities, inflammatory-marker. |
Field | Medical / Pharmacy |
Published In | Volume 6, Issue 4, July-August 2024 |
Published On | 2024-08-24 |
Cite This | A study of determinants of pulmonary fibrosis in COVID-19 survivors. - Raj Kumar, Rajiv Garg, Surya Kant, S.K. Verma, Santosh Kumar, R.A.S. Kushwaha, Ajay Kumar Verma, Anand Srivastava, Darshan Kumar Bajaj, Ankita Mandal - IJFMR Volume 6, Issue 4, July-August 2024. DOI 10.36948/ijfmr.2024.v06i04.26339 |
DOI | https://doi.org/10.36948/ijfmr.2024.v06i04.26339 |
Short DOI | https://doi.org/gt8g6s |
Share this
E-ISSN 2582-2160
doi
CrossRef DOI is assigned to each research paper published in our journal.
IJFMR DOI prefix is
10.36948/ijfmr
Downloads
All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.